¼¼°èÀÇ Áٱ⼼Æ÷ Á¦Á¶ ½ÃÀå º¸°í¼­(2025³â)
Stem Cell Manufacturing Global Market Report 2025
»óǰÄÚµå : 1821703
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Áٱ⼼Æ÷ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡ CAGRÀº 11.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í 300¾ï 3,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ÀÚ±Ý ¹× ÅõÀÚ Áõ°¡, Ä¡·áÁ¦ ¿ëµµ È®´ë, ¼¼Æ÷ ±â¹Ý Ä¡·á¹ý µîÀå, ÀÓ»ó ½ÃÇè ¹× ½ÂÀÎ Áõ°¡, ¸ÂÃãÇü ¹× ȯÀÚº° Ä¡·á¹ý ¹ßÀü¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ¿¡ ÁÖ·Â, À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) È®´ë, ÀÚµ¿È­ ¹× ·Îº¿ ÅëÇÕ, Ç¥ÁØÈ­ ¹× È®À强, »ý¹°¹ÝÀÀ±â ±â¼úÀû ¹ßÀü µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÇâÈÄ 5³â°£ 11.9% ¼ºÀå ¿¹ÃøÀº ÀÌÀü Àü¸Á ´ëºñ 0.2% ¼ÒÆø Ç϶ôÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ Ç϶ôÀº ÁÖ·Î ¹Ì±¹°ú Ÿ±¹ °£ °ü¼¼ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. ¹«¿ª ±äÀåÀº À̽º¶ó¿¤°ú º§±â¿¡¿¡¼­ °³¹ßµÈ ÀÚµ¿È­ »ý¹°¹ÝÀÀ±â ½Ã½ºÅÛ ¹× GMP µî±Þ ¼ºÀåÀÎÀÚÀÇ °¡°Ý »ó½ÂÀ» À¯¹ßÇÏ¿© ¹Ì±¹ ¼¼Æ÷ Ä¡·áÁ¦ »ý»êÀ» ÀúÇØÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Á¦Á¶ º´¸ñ Çö»ó°ú CAR-T Ä¡·á ºñ¿ë Áõ°¡·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼ ºÎ°ú¿Í ¹«¿ª ±äÀå ¹× Á¦ÇÑ °­È­·Î ÀÎÇÑ Àü ¼¼°è °æÁ¦ ¹× ¹«¿ª¿¡ ´ëÇÑ ºÎÁ¤Àû ¿µÇâÀ¸·Î ±× È¿°ú°¡ ´õ¿í ±¤¹üÀ§ÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

³ëÀÎ Àα¸ Áõ°¡°¡ Áٱ⼼Æ÷ Á¦Á¶ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀÎ Àα¸´Â ¸é¿ª·Â °¨Ãà°ú ³ëÈ­ ¿µÇâÀ¸·Î ´Ù¾çÇÑ °Ç°­ ¹®Á¦¸¦ °Þ´Â 65¼¼ ÀÌ»ó °³ÀÎÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ Àα¸ Áý´ÜÀº ¸¸¼º Áúȯ À§ÇèÀÌ ³ôÀ¸¸ç, Áٱ⼼Æ÷ Á¦Á¶´Â ÀÌ·¯ÇÑ Áúȯ ÅðÄ¡¿¡ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù, ÄɳĿ¡ º»ºÎ¸¦ µÐ ºñ¿µ¸® ´ÜüÀÎ Àα¸¹®Á¦¿¬±¸¼Ò´Â 65¼¼ ÀÌ»óÀÇ ¹Ì±¹ÀÎ ¼ö°¡ 2022³â 5,800¸¸¸í¿¡¼­ 2050³â¿¡ 8,200¸¸¸íÀ¸·Î 47% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù°í º¸°íÇß½À´Ï´Ù. ¶ÇÇÑ ÀÌ ¿¬·É´ë°¡ ÃÑ Àα¸¿¡¼­ Â÷ÁöÇÏ´Â ºñÀ²Àº °°Àº ½Ã±â¿¡ 17%¿¡¼­ 23%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µû¶ó¼­ È®´ëµÇ´Â °í·É Àα¸´Â Áٱ⼼Æ÷ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀå¿¡ »ó´çÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Stem cell manufacturing involves the technologies required to transition stem cell tissue culture from laboratory settings to clinical applications, ensuring controlled, reproducible, automated, validated, and safe production for therapeutic purposes.

The primary products within stem cell manufacturing comprise consumables, instruments, and stem cell lines. Consumables are utilized in growing new cells within culture media, contributing to applications in drug development, tissue culture, gene therapy, and toxicity testing. These consumables serve diverse purposes across research, clinical applications, and cell and tissue banking. They are used by a range of end-users including pharmaceutical and biotechnology companies, academic institutes, research laboratories, contract research organizations, hospitals and surgical centers, as well as cell and tissue banks.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The stem cell manufacturing market research report is one of a series of new reports from The Business Research Company that provides stem cell manufacturing market statistics, including stem cell manufacturing industry global market size, regional shares, competitors with a stem cell manufacturing market share, detailed stem cell manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell manufacturing industry. This stem cell manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell manufacturing market size has grown strongly in recent years. It will grow from $17.5 billion in 2024 to $19.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to advancements in biotechnology, research and development initiatives, clinical trials and therapeutic applications, regulatory framework establishment, investment in infrastructure.

The stem cell manufacturing market size is expected to see rapid growth in the next few years. It will grow to $30.03 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increased funding and investments, growing therapeutic applications, emergence of cell-based therapies, rise in clinical trials and approvals, customized and patient-specific therapies. Major trends in the forecast period include focus on 3d bioprinting, expansion in induced pluripotent stem cells (ipscs), automation and robotics integration, standardization and scalability, bioreactor technology advancements.

The forecast of 11.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cell therapy production by inflating prices of automated bioreactor systems and GMP-grade growth factors developed in Israel and Belgium, resulting in manufacturing bottlenecks and higher CAR-T therapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing geriatric population is anticipated to drive the growth of the stem cell manufacturing market. The geriatric population refers to individuals aged 65 and older, who often experience various health issues due to reduced immunity and the effects of aging. This demographic faces a higher risk of chronic diseases, and stem cell manufacturing can play a crucial role in combating these ailments. For example, in January 2024, the Population Reference Bureau, a nonprofit organization based in Kenya, reported that the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, this age group is expected to grow its share of the total population from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is a significant driver of the stem cell manufacturing market's growth.

The expanding biotechnology industry is projected to drive the growth of the stem cell manufacturing market in the future. Biotechnology is a broad and rapidly evolving field that includes a variety of products and services utilizing living organisms or their components to create new technologies and solutions. Stem cell manufacturing represents a quickly advancing sector with the potential to transform the biotechnology landscape by developing innovative therapies and treatments for various diseases. For instance, in June 2024, the BioIndustry Association (BIA), a UK-based national trade association for the life sciences and biotechnology sector, reported that biotech companies in the UK secured £622 million in venture capital during the second quarter of 2024, marking an impressive 259% increase from the previous quarter and a 48% rise compared to the same period last year. Thus, the growth of the biotechnology industry is fueling the expansion of the stem cell manufacturing market.

Technological advancement is a significant trend within the stem cell manufacturing market. Various stakeholders are concentrating on utilizing advanced technologies to remain competitive in the industry. For example, in August 2022, Bluebird Bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNTEGLO. This groundbreaking one-time gene therapy is now authorized for treating beta-thalassemia in patients requiring regular red blood cell transfusions. A key feature of this therapy is its ex-vivo method, where a modified beta-globin gene is integrated into the patient's own hematopoietic stem cells, allowing them to produce normal levels of hemoglobin. This innovative treatment aims to achieve transfusion independence, significantly reducing the treatment burden for individuals with beta-thalassemia. The approval of ZYNTEGLO marks a pivotal milestone in gene therapy, potentially providing a cure and improving the quality of life for those affected.

Major companies within the stem cell manufacturing market are actively pursuing the development of innovative products, with a focus on GM-grade protein to attain a competitive advantage. GM-grade protein is a designation indicating that protein powders and related products meet specific standards for quality and safety. A noteworthy example is ACROBiosystems Inc., a US-based provider of recombinant proteins and critical reagents, which, in November 2023, introduced GM-grade DLL4 protein. This recombinant, soluble form of Delta-such as Ligand 4 (DLL4), a crucial signaling molecule in stem cell development and differentiation, signifies a significant milestone for advancing stem cell-based therapies. The availability of GMP-grade DLL4 ensures a high-quality, consistent, and scalable source of this essential protein, known for promoting the self-renewal and expansion of hematopoietic stem cells (HSCs). Its utilization in stem cell cultures enhances the growth and differentiation of HSCs, contributing to advancements in stem cell research and therapies.

In July 2022, Bio-Techne Corporation, a US-based life sciences company, acquired Namocell Inc. for an undisclosed sum. This strategic acquisition enhances Bio-Techne's capabilities in stem cell research and manufacturing by integrating Namocell's innovative platforms, which are crucial for cell and gene therapy development, cell engineering, and single-cell genomics. Namocell Inc. specializes in high-performance systems for single-cell sorting and dispensing.

Major companies operating in the stem cell manufacturing market include Thermo Fisher Scientific Inc., Merck Millipore, Stemcell Technologies, Fujifilm Holdings Corporation, Takara Bio Group, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Becton Dickinson and Company, Bio-Techne Corporation, Miltenyi Biotec, Terumo BCT Inc., Corning Inc., Eppendorf AG, ViaCyte Inc., Merck KGaA, Danaher Corporation, Vericel Corporation, American Cryostem Corporation, Cellgenix GMBH, Aspen Neuroscience Inc., Magenta Therapeutics Inc, Pluristem Therapeutics Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., 3D Biomatrix Inc., Worthington Biochemical Corporation, Bico Group

North America was the largest region in the stem cell manufacturing market in 2024. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the stem cell manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stem cell manufacturing market consists of sales of adult stem cells (ASCs), human embryonic stem cells (HESCs), induced pluripotent stem cells (iPSCs), and very small embryonic-such as cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stem Cell Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stem cell manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for stem cell manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Stem Cell Manufacturing Market Characteristics

3. Stem Cell Manufacturing Market Trends And Strategies

4. Stem Cell Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Stem Cell Manufacturing Growth Analysis And Strategic Analysis Framework

6. Stem Cell Manufacturing Market Segmentation

7. Stem Cell Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Stem Cell Manufacturing Market

9. China Stem Cell Manufacturing Market

10. India Stem Cell Manufacturing Market

11. Japan Stem Cell Manufacturing Market

12. Australia Stem Cell Manufacturing Market

13. Indonesia Stem Cell Manufacturing Market

14. South Korea Stem Cell Manufacturing Market

15. Western Europe Stem Cell Manufacturing Market

16. UK Stem Cell Manufacturing Market

17. Germany Stem Cell Manufacturing Market

18. France Stem Cell Manufacturing Market

19. Italy Stem Cell Manufacturing Market

20. Spain Stem Cell Manufacturing Market

21. Eastern Europe Stem Cell Manufacturing Market

22. Russia Stem Cell Manufacturing Market

23. North America Stem Cell Manufacturing Market

24. USA Stem Cell Manufacturing Market

25. Canada Stem Cell Manufacturing Market

26. South America Stem Cell Manufacturing Market

27. Brazil Stem Cell Manufacturing Market

28. Middle East Stem Cell Manufacturing Market

29. Africa Stem Cell Manufacturing Market

30. Stem Cell Manufacturing Market Competitive Landscape And Company Profiles

31. Stem Cell Manufacturing Market Other Major And Innovative Companies

32. Global Stem Cell Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Stem Cell Manufacturing Market

34. Recent Developments In The Stem Cell Manufacturing Market

35. Stem Cell Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â